A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

J&J’s One-Dose COVID-19 Vaccine Shows 72% Efficacy in the US


Results from Phase 3 clinical trials on Johnson & Johnson’s (J&J) one-dose COVID-19 vaccine demonstrated 72% effectiveness against moderate to severe COVID-19-related illness in the United States. However, this rate dropped to 57% in trials conducted in South Africa, which suggests the vaccine is less able to fight off the new variant that is highly present in the region. The effectiveness of the J&J vaccine is high enough to meet the US Food and Drug Administration’s requirements for Emergency Use Authorization but is lower than the Pfizer and Moderna vaccines, which are approximately 95% effective. However, the J&J vaccine requires only one dose and does not need sub-zero storage, which could help efforts to get more individuals vaccinated as quickly as possible. Click here to read more.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy